FCRL2 and B-cell chronic lymphocytic leukemia: Analysis of a M-CLL sample stained indirectly with the previously described anti-FCRL2-mAb 7F2 (biotinylated and co-stained with SA-PE) versus directly with 3E11-PE revealed stronger MFI reactivity for the latter mAb (Fig. 1b).